Tacoma、WAにおける乳がんの臨床試験
Tacomaとその周辺地域（約30マイル以内）の拠点で、乳がんに関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Madigan Army Medical Center, Tacoma
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Northwest Medical Specialties, Tacoma
- Providence Regional Cancer System, Lacey · 23マイル先
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Providence Regional Cancer System-Lacey, Lacey · 23マイル先
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
被験者募集中第3相
- Research Site, Puyallup · 8マイル先
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- Northwest Medical Specialties, Puyallup · 8マイル先
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
被験者募集中第3相
- Northwest Medical Specialties, PLLC ( Site 0062), Tacoma
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Tacoma
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
被験者募集中第3相
- Northwest Medical Specialties, Tacoma
- Northwest Medical Specialties, Gig Harbor · 8マイル先
- Northwest Medical Specialties, Puyallup · 8マイル先
- 他1件
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
被験者募集中第3相
- Northwest Medical Specialties, PLLC ( Site 0067), Tacoma
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- MultiCare Cancer Institute, Tacoma
- Northwest Medical Specialties, PLLC, Puyallup · 8マイル先
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, Olympia · 26マイル先
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- MultiCare Health System, Tacoma
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- Northwest Medical Specialties, PLLC, Tacoma
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- MultiCare Cancer Institute - Tacoma, Tacoma
- Northwest Medical Specialties PLLC, Tacoma
- Vista Oncology, Olympia · 26マイル先
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Northwest Medical Specialties, Tacoma
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Providence Regional Cancer System-Lacey, Lacey · 23マイル先
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Northwest Medical Specialties, PLLC, Tacoma
BostonGene and Exigent Genomic INsight Study
被験者募集中観察研究
- Northwest Medical Specialities, Puyallup · 8マイル先
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Tacomaにおける他の研究
- 非小細胞肺癌20件の研究
- 潰瘍性大腸炎15件の研究
- 多発性骨髄腫13件の研究
- 前立腺がん11件の研究
- クローン病11件の研究
- 大腸癌9件の研究
- 転移性癌9件の研究
- 悪性黒色腫7件の研究
- 卵巣がん7件の研究
- 胃癌6件の研究
- 食道癌6件の研究
- がん（全種類）6件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。